• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Golumbeski George

    6/13/25 8:00:05 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Golumbeski George

    (Last) (First) (Middle)
    C/O MURAL ONCOLOGY PLC
    10 EARLSFORT TERRACE

    (Street)
    DUBLIN 2 L2 D02 T380

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mural Oncology plc [ MURA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $2.56 06/11/2025 A 8,637 (1) 06/10/2035 Ordinary Shares 8,637 $0.00 8,637 D
    Explanation of Responses:
    1. This option was granted on June 11, 2025. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer.
    /s/ Maiken Keson-Brookes, attorney-in-fact for George Golumbeski 06/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MURA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MURA

    DatePrice TargetRatingAnalyst
    3/25/2025Overweight → Equal-Weight
    Morgan Stanley
    3/25/2025$18.00Strong Buy → Outperform
    Raymond James
    6/28/2024$15.00Buy
    Rodman & Renshaw
    4/4/2024$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $MURA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mural Oncology Announces Plans to Explore Strategic Alternatives

      Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company, today announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer

      4/15/25 8:00:00 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

      Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally consistent with previously reported data; over 800 patients treated across the greater nemvaleukin clinical program The company remains on track to share topline results from potentially registrational, phase 2 trial in mucosal melanoma, ARTISTRY-6, Cohort 2, evaluating nemvaleukin monotherapy in Q2 2025 WALTHAM, Mass and DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company, today announced that the ARTISTR

      3/25/25 6:30:00 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

      Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melanoma expected in Q2 2025 Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin alfa in the ARTISTRY-6 trial in patients with cutaneous melanoma expected in 1H 2025 for monotherapy (cohort 3) and 2H 2025 for combination therapy (cohort 4) Cash runway extended into Q1 2026 through operational efficiencies WALTHAM, Mass. and DUBLIN, March 11, 2025 (GLOBE NEWSWIRE) -- Mural Oncolog

      3/11/25 4:01:00 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mural Oncology downgraded by Morgan Stanley

      Morgan Stanley downgraded Mural Oncology from Overweight to Equal-Weight

      3/25/25 12:58:54 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mural Oncology downgraded by Raymond James with a new price target

      Raymond James downgraded Mural Oncology from Strong Buy to Outperform and set a new price target of $18.00

      3/25/25 11:43:59 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Mural Oncology with a new price target

      Rodman & Renshaw initiated coverage of Mural Oncology with a rating of Buy and set a new price target of $15.00

      6/28/24 8:19:17 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Altschuller Susan bought $32,071 worth of Ordinary Shares (10,000 units at $3.21) (SEC Form 4)

      4 - Mural Oncology plc (0001971543) (Issuer)

      8/15/24 4:15:04 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Cuss Francis M

      4 - Mural Oncology plc (0001971543) (Issuer)

      6/13/25 8:00:09 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hickey Benjamin

      4 - Mural Oncology plc (0001971543) (Issuer)

      6/13/25 8:00:04 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Minegishi Sachiyo

      4 - Mural Oncology plc (0001971543) (Issuer)

      6/13/25 8:00:08 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    SEC Filings

    See more
    • SEC Form 8-K filed by Mural Oncology plc

      8-K - Mural Oncology plc (0001971543) (Filer)

      6/12/25 4:17:32 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc

      SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

      5/15/25 3:44:38 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc

      SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

      5/15/25 11:17:04 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    Leadership Updates

    Live Leadership Updates

    See more
    • Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

      Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

      11/13/24 7:00:00 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

      Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

      9/26/24 7:00:00 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

      WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

      9/23/24 7:00:00 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    Financials

    Live finance-specific insights

    See more
    • Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

      Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melanoma expected in Q2 2025 Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin alfa in the ARTISTRY-6 trial in patients with cutaneous melanoma expected in 1H 2025 for monotherapy (cohort 3) and 2H 2025 for combination therapy (cohort 4) Cash runway extended into Q1 2026 through operational efficiencies WALTHAM, Mass. and DUBLIN, March 11, 2025 (GLOBE NEWSWIRE) -- Mural Oncolog

      3/11/25 4:01:00 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

      Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company's ongoing phase 2 trial in patients with melanoma Mural Oncology intends to nominate development candidates for its engineered therapies targeting interleukin-18 and interleukin-12 in 2024 The company reiterates cash runway projection into 4Q 2025 WALTHAM, Mass. and DUBLIN, Ireland, March 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology

      3/26/24 7:00:00 AM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

      SC 13G/A - Mural Oncology plc (0001971543) (Subject)

      11/14/24 5:15:53 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

      SC 13G/A - Mural Oncology plc (0001971543) (Subject)

      11/12/24 3:52:44 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

      SC 13G/A - Mural Oncology plc (0001971543) (Subject)

      11/4/24 2:39:13 PM ET
      $MURA
      Biotechnology: Pharmaceutical Preparations
      Health Care